🇺🇸 FDA

Intelligence · Clinical Pipeline

R&D Pipeline Programs

ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.

Programs indexed
20,548
Companies
1,769
Drugs tracked
4,797

Quick answer

NovaPharmaNews tracks 20,548 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.

122 results for “BEONE MEDICINES AUS PTY LTD” Clear

  1. PD-1/PD-L1 inhibitors

    BEONE MEDICINES AUS PTY LTD

    Borderline Resectable Carcinoma

    phase 2 small molecule active

    1 trial

  2. Rituximab

    BEONE MEDICINES AUS PTY LTD

    Chronic Lymphocytic Leukemia

    phase 2 mab active

    1 trial

  3. Sonrotoclax

    BEONE MEDICINES AUS PTY LTD

    Relapsed/Refractory Multiple Myeloma

    phase 2 small molecule active

    1 trial

  4. Sonrotoclax

    BEONE MEDICINES AUS PTY LTD

    Waldenstrom Macroglobulinemia

    phase 2 small molecule active

    1 trial

  5. Surzebiclimab

    BEONE MEDICINES AUS PTY LTD

    Locally Advanced or Metastatic Solid Tumors for Phase 1, Dose Escalation and Phase 2 Safety Lead-in

    phase 2 small molecule completed

    1 trial

  6. Tislelizumab

    BEONE MEDICINES AUS PTY LTD

    Gastroesophageal Adenocarcinoma

    phase 2 small molecule active

    1 trial

  7. Tislelizumab

    BEONE MEDICINES AUS PTY LTD

    Advanced Unresectable Gastric Adenocarcinoma

    phase 2 small molecule active

    1 trial

  8. Tislelizumab

    BEONE MEDICINES AUS PTY LTD

    Colorectal Cancer

    phase 2 small molecule completed

    1 trial

  9. Tislelizumab

    BEONE MEDICINES AUS PTY LTD

    Resectable Esophageal Squamous Cell Carcinoma

    phase 2 small molecule completed

    1 trial

  10. Tislelizumab (BGB-A317)

    BEONE MEDICINES AUS PTY LTD

    MSI-H/dMMR Solid Tumors

    phase 2 small molecule active

    1 trial

  11. Tunlametinib+PD-1 mAb

    BEONE MEDICINES AUS PTY LTD

    Gastric Adenocarcinoma

    phase 2 small molecule active

    1 trial

  12. ZW25 (Zanidatamab)

    BEONE MEDICINES AUS PTY LTD

    HER2-amplified Biliary Tract Cancers

    phase 2 small molecule completed

    1 trial

  13. Zanubrutinib

    BEONE MEDICINES AUS PTY LTD

    Diffuse Large B-cell Lymphoma (DLBCL)

    phase 2 small molecule active

    1 trial

  14. Zanubrutinib

    BEONE MEDICINES AUS PTY LTD

    Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma

    phase 2 small molecule completed

    1 trial

  15. Zanubrutinib

    BEONE MEDICINES AUS PTY LTD

    Chronic Lymphocytic Leukemia (CLL)

    phase 2 small molecule active

    1 trial

  16. Zanubrutinib

    BEONE MEDICINES AUS PTY LTD

    Relapsed Diffuse Large B-cell Lymphoma

    phase 2 small molecule completed

    1 trial

  17. Zanubrutinib

    BEONE MEDICINES AUS PTY LTD

    Mature B-cell Malignancies

    phase 2 small molecule completed

    1 trial

  18. Zanubrutinib

    BEONE MEDICINES AUS PTY LTD

    Relapsed/Refractory Follicular Non-Hodgkin Lymphoma

    phase 2 small molecule completed

    1 trial

  19. Zanubrutinib

    BEONE MEDICINES AUS PTY LTD

    Mantle Cell Lymphoma

    phase 2 small molecule active

    1 trial

  20. Zanubrutinib

    BEONE MEDICINES AUS PTY LTD

    Follicular Lymphoma

    phase 2 small molecule active

    1 trial

  21. Zanubrutinib, BGB-11417, BGB-11417

    BEONE MEDICINES AUS PTY LTD

    previously untreated WM, Relapsed/Refractory Waldenström’s Macroglobulinemia

    phase 2 small molecule active

    1 trial

  22. long course radiotherapy + capecitabine + PD-1 monoclonal antibody treatment combinations

    BEONE MEDICINES AUS PTY LTD

    Colorectal Neoplasms

    phase 2 other active

    1 trial

  23. A Multicenter, Open-Label, Phase 1a/b First-in-Human Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Preliminary Antitumor Activity of BG-C0979 in Patients with Selected Advanced Solid Tumors

    BEONE MEDICINES AUS PTY LTD

    Advanced Solid Tumors

    phase 1 other active

    1 trial

  24. A Phase 1 Study Investigating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Antitumor Activity of BGB-B2033, Alone or in Combination With Tislelizumab With or Without Bevacizumab, in Participants With Selected Advanced or Metastatic Solid Tumors

    BEONE MEDICINES AUS PTY LTD

    Selected Advanced or Metastatic Solid Tumors

    phase 1 other active

    1 trial

Frequently asked questions

What is the NovaPharmaNews pipeline directory?

It is a searchable index of 20,548 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.

Where does pipeline data come from?

Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.

How do I find pipeline programs by company or phase?

Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.

Data attribution and licensing: Data sources